# US 2010/0168208 A1 · RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168208 A1
- Document ID: US20100168208A1
- Status: Published application
- Kind: A1
- Application number: 12/640,411
- Filed: 2009-12-17
- Published: 2010-07-01
- Earliest claimed: 2001-08-15
- Assignees: Sima Therapeutics, Inc.
- Inventors: James McSwiggen; Leonid Beigelman
- Web page: https://patentgrep.com/patent/US20100168208A1

## CPC

- A61K 49/0008: {Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1132: {against retroviridae, e.g. HIV}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- C12N 15/87: Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12Y 103/01022: 3-Oxo-5alpha-steroid 4-dehydrogenase (NADP+) (1.3.1.22), i.e. cortisone alpha-reductase
- C12Y 104/03003: D-Amino-acid oxidase (1.4.3.3)
- C12Y 114/19001: Stearoyl-CoA 9-desaturase (1.14.19.1), i.e. DELTA9-desaturase
- C12Y 207/07049: RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
- C12Y 207/11001: Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
- C12Y 207/11013: Protein kinase C (2.7.11.13)
- C12Y 301/03048: Protein-tyrosine-phosphatase (3.1.3.48)
- C12Y 604/01002: Acetyl-CoA carboxylase (6.4.1.2)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2310/111: spanning the whole gene, or a large part of it
- C12N 2310/12: catalytic nucleic acids, e.g. ribozymes
- C12N 2310/121: Hammerhead
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C12N 2310/317: with an inverted bond, e.g. a cap structure
- C12N 2310/318: where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N 2310/332: Abasic residue
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N 2310/53: partially self-complementary or closed
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N 2330/30: chemically synthesised
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present invention concerns methods and reagents useful in modulating BACE gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against beta-secretase (BACE), amyloid precursor protein (APP), pin-1, presenillin 1 (PS-1) and/or presenillin 2 (PS-2) gene expression and/or activity. The small nucleic acid molecules are useful in the treatment of Alzheimer's disease and any other condition that responds to modulation of BACE, APP, pin-1, PS-1 and/or PS-2 expression or activity.

## Claims

### Claim 1

A chemically modified nucleic acid molecule, wherein:
(a) the nucleic acid molecule comprises a sense strand and a separate antisense strand, each strand having one or more pyrimidine nucleotides and one or more purine nucleotides;
(b) each strand of the nucleic acid molecule is independently 18 to 27 nucleotides in length;
(c) an 18 to 27 nucleotide sequence of the antisense strand is complementary to a human beta-secretase (BACE) RNA sequence comprising SEQ ID NO:709;
(d) the sense strand has a Stab 7 stabilization chemistry configuration, wherein each pyrimidine nucleotide has a 2′-fluoro modification, each purine nucleotide has a 2′-deoxy modification and both the 5′- and 3′-ends have a terminal cap moiety;
(e) the antisense strand has a Stab 11 stabilization chemistry configuration, wherein each pyrimidine nucleotide has a 2′-fluoro modification, each purine nucleotide has a 2′-deoxy modification and the antisense strand has a phosphorothioate internucleotide linkage at the 3′-end; and
(f) wherein the nucleic acid molecule mediates RNA interference.

### Claim at position 2

2-14. (canceled)

### Claim 15 (depends on 1)

The nucleic acid molecule of claim 1, wherein the terminal cap moiety is an inverted deoxy abasic moiety.

### Claim 16 (depends on 1)

The nucleic acid molecule of claim 1, wherein said nucleic acid molecule includes two or more phosphorothioate internucleotide linkages.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The nucleic acid molecule of claim 1, wherein the 5′-end of the antisense strand includes a terminal phosphate group.

### Claim 19 (depends on 1)

The nucleic acid molecule of claim 1, wherein the sense strand, the antisense strand, or both the sense strand and the antisense strand include a 3′-overhang.

### Claim 20 (depends on 1)

A composition comprising the nucleic acid molecule of claim 1, in a pharmaceutically acceptable carrier or diluent.

### Claim 21 (depends on 19)

The nucleic acid molecule of claim 19, wherein both the sense and the antisense strand include a 3′-overhang.

### Claim 22 (depends on 19)

The nucleic acid molecule of claim 19, wherein the 3′-overhang comprises 1-4 nucleotides in length.

### Claim 23 (depends on 19)

The nucleic acid molecule of claim 19, wherein the 3′-overhang comprises thymidine residues.

### Claim 24 (depends on 19)

The nucleic acid molecule of claim 19, wherein the overhang comprises ribonucleotides.

### Claim 25 (depends on 19)

The nucleic acid molecule of claim 19 wherein the overhang comprises ribonucleotides that are chemically modified at a nucleic acid sugar, base, or backbone.

### Claim 26 (depends on 1)

The nucleic acid molecule of claim 1, comprising one or more blunt ends.
